AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35266148 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline peanut-reactive TH2A cells
Number of subjects: 0
Study 35266148 — intervention group
Group type: EXPERIMENTAL
Intervention: POIT
Number of subjects: 0
Study 35266148 — intervention group
Group type: EXPERIMENTAL
Intervention: AR101 therapy
Number of subjects: 0
Study 35266148 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut-reactive Treg cell frequency
Number of subjects: 0
Study 33595923 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic pulsatility index (API)
Number of subjects: 433
Study 33595923 — intervention group
Group type: COMPARATOR
Intervention: Cardiac power output (CPO)
Number of subjects: 433
Study 33595923 — intervention group
Group type: COMPARATOR
Intervention: Fick cardiac index (CI)
Number of subjects: 433
Study 33595923 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery pulsatility index (PAPI)
Number of subjects: 433
Study 32539121 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (initial dose of 10 mg/kg followed by 5 mg/kg after 24 hours and a second 5 mg/kg dose after 48 hours)
Number of subjects: 146
Study 32539121 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention
Number of subjects: 146
Study 32539121 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 146
Study 35012375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital with visible greenspaces
Number of subjects: 74
Study 35012375 — intervention group
Group type: COMPARATOR
Intervention: Hospital without visible greenspaces
Number of subjects: 74
Study 34156002 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal blockade of the nasopalatine nerve at the point of its emergence from the pterygopalatine ganglion
Number of subjects: 52
Study 34156002 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia of the nasopalatine nerve at its entry into the incisive canal
Number of subjects: 52
Study 34273071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0
Study 34273071 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 0
Study 34273071 — intervention group
Group type: EXPERIMENTAL
Intervention: All other azole antifungals
Number of subjects: 0
Study 34273071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (CYP 3A inhibition confirmed with midazolam)
Number of subjects: 0
Study 32282386 — intervention group
Group type: COMPARATOR
Intervention: DPE + CEI
Number of subjects: 116
Study 32282386 — intervention group
Group type: COMPARATOR
Intervention: DPE + PIEB
Number of subjects: 116
Study 32282386 — intervention group
Group type: COMPARATOR
Intervention: EP + CEI
Number of subjects: 116
Study 36335411 — intervention group
Group type: COMPARATOR
Intervention: Oral or sublingual mixed respiratory bacterial lysates (BLs)
Number of subjects: 1658
Study 36335411 — intervention group
Group type: COMPARATOR
Intervention: Injected mixed respiratory bacterial vaccines (BVs)
Number of subjects: 1658
Study 32680615 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 20
Study 32680615 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20
Study 32680615 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 20
Study 32680615 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 20
Study 35534349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Synergy and Xience stents
Number of subjects: 170
Study 32209907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate incision
Number of subjects: 209
Study 32209907 — intervention group
Group type: COMPARATOR
Intervention: Circular incision
Number of subjects: 209
Study 32209907 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic mesh
Number of subjects: 209
Study 35435203 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE/C group (alternate rapid palatal expansions and constrictions with facemask protraction)
Number of subjects: 34
Study 35435203 — intervention group
Group type: COMPARATOR
Intervention: RPE group (rapid palatal expansion with facemask protraction)
Number of subjects: 34
Study 33730122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor (NGF) injection into SCM
Number of subjects: 28
Study 33730122 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution injection into SCM
Number of subjects: 28
Study 35232309 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictions on potential allocations to ensure balance across study arms
Number of subjects: 0
Study 35232309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher–Bailey validity
Number of subjects: 0
Study 35043507 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically administered purified clinoptilolite-tuff (PCT)
Number of subjects: 0
Study 35043507 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 0
Study 32757963 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided discontinuation of antimicrobials
Number of subjects: 266
Study 32757963 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 266
Study 33960817 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftobiprole
Number of subjects: 633
Study 33960817 — intervention group
Group type: COMPARATOR
Intervention: comparator antibiotics
Number of subjects: 633
Study 32885600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 0
Study 32885600 — intervention group
Group type: COMPARATOR
Intervention: Gastric bypass
Number of subjects: 0
Study 34171870 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive esophagectomy (RAMIE)
Number of subjects: 0
Study 32823510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary practices of adolescents (e.g., sugary snacks, breakfast consumption)
Number of subjects: 1360
Study 32823510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary practices of females
Number of subjects: 1360
Study 32823510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary practices in rural areas
Number of subjects: 1360
Study 32823510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary practices in urban areas
Number of subjects: 1360
Study 33526030 — intervention group
Group type: EXPERIMENTAL
Intervention: CARD™ intervention (C-Comfort, A-Ask, R-Relax, D-Distract)
Number of subjects: 219
Study 33526030 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 219
Study 33285419 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded PrEP alone
Number of subjects: 0
Study 33285419 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing alone
Number of subjects: 0
Study 33285419 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing alongside ART + PrEP
Number of subjects: 0
Study 33285419 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded ART alone
Number of subjects: 0
Study 33285419 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling up PrEP alone
Number of subjects: 0
Study 33285419 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing (alone or with ART + PrEP)
Number of subjects: 0
Study 36261400 — intervention group
Group type: EXPERIMENTAL
Intervention: O-R toothbrush (Oral-B iO with Radiant White brush head)
Number of subjects: 100
Study 36261400 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Oral-B Indicator)
Number of subjects: 100
Study 34254372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornus mas L. fruit extract (CMFE)
Number of subjects: 50
Study 34254372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35006328 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate therapy (CHO) group received a 400‐mL carbohydrate drink 2‐3 hours before anesthesia
Number of subjects: 50
Study 35006328 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent overnight fasting from midnight, one night before surgery
Number of subjects: 50
Study 35006328 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate therapy (CHO) group
Number of subjects: 50
Study 33235033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=142)
Number of subjects: 280
Study 33235033 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=138)
Number of subjects: 280
Study 33235033 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium levels of PA
Number of subjects: 280
Study 33235033 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of PA
Number of subjects: 280
Study 33235033 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity PA
Number of subjects: 280
Study 33235033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity PA
Number of subjects: 280
Study 34112291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oro-esophageal tube feeding (IOE) combined with Xuanqiaoliyan decoction
Number of subjects: 100
Study 34112291 — intervention group
Group type: COMPARATOR
Intervention: Routine swallowing function training (control group)
Number of subjects: 100
Study 35543940 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming acupuncture combined with 'three steps and seven methods' of tuina
Number of subjects: 138
Study 35543940 — intervention group
Group type: COMPARATOR
Intervention: Simple 'three steps and seven methods' of tuina
Number of subjects: 138
Study 33210831 — intervention group
Group type: EXPERIMENTAL
Intervention: TALK SWI
Number of subjects: 300
Study 33210831 — intervention group
Group type: EXPERIMENTAL
Intervention: TALK SWI plus Living Donor Financial Assistance
Number of subjects: 300
Study 33210831 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 300
Study 35689033 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (wrist motion exercise immediately after surgery)
Number of subjects: 48
Study 35689033 — intervention group
Group type: COMPARATOR
Intervention: Delayed mobilization (wrist motion exercise after 2 weeks of external immobilization)
Number of subjects: 48
Study 34760020 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplementation (one tablet daily for three consecutive cycles)
Number of subjects: 129
Study 34760020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet daily for three consecutive cycles)
Number of subjects: 129
Study 36184780 — intervention group
Group type: EXPERIMENTAL
Intervention: tirzepatide 5 mg
Number of subjects: 48
Study 36184780 — intervention group
Group type: EXPERIMENTAL
Intervention: tirzepatide 10 mg
Number of subjects: 48
Study 36184780 — intervention group
Group type: EXPERIMENTAL
Intervention: tirzepatide 15 mg
Number of subjects: 48
Study 36184780 — intervention group
Group type: COMPARATOR
Intervention: dulaglutide 0.75 mg
Number of subjects: 48
Study 33685969 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 82
Study 33685969 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 82
Study 32698790 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab and atezolizumab
Number of subjects: 201
Study 32698790 — intervention group
Group type: COMPARATOR
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 201
Study 35998958 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative support programme consisting of four face-to-face intervention sessions during the hospital stay and two weekly telephone follow-up sessions after discharge.
Number of subjects: 0
Study 35998958 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 34096755 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychedelic-assisted psychotherapy (PAP) using compounds such as MDMA, psilocybin, and LSD
Number of subjects: 0
Study 34096755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32017253 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 1,000 mg/day for 3 months
Number of subjects: 70
Study 32017253 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 70
Study 36224529 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based holistic health-care education (3.5 hours)
Number of subjects: 30
Study 32617578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren added to an angiotensin II receptor blocker (ARB)
Number of subjects: 76
Study 32617578 — intervention group
Group type: COMPARATOR
Intervention: Control (ARB alone)
Number of subjects: 76
Study 32617578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 76
Study 32617578 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 32671537 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1
Number of subjects: 120
Study 32671537 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2
Number of subjects: 120
Study 32671537 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 3
Number of subjects: 120
Study 32671537 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 4
Number of subjects: 120
Study 34898303 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 levels on day-5
Number of subjects: 96
Study 34898303 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operating Curve analysis for day-5 Endothelin-1
Number of subjects: 96
Study 36974773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 8537
Study 36974773 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 8537
Study 36974773 — intervention group
Group type: EXPERIMENTAL
Intervention: Less fit status
Number of subjects: 8537
Study 36974773 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail status
Number of subjects: 8537
Study 32767696 — intervention group
Group type: COMPARATOR
Intervention: Control group of a randomized controlled trial testing a care transitions intervention
Number of subjects: 699
Study 32936595 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 30
Study 32936595 — intervention group
Group type: COMPARATOR
Intervention: Sedentary behavior (SB)
Number of subjects: 30
Study 36256673 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cough technique (SCT)
Number of subjects: 6
Study 36256673 — intervention group
Group type: COMPARATOR
Intervention: Forced expiration technique (FET)
Number of subjects: 6
Study 36256673 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline inhalation with SCT
Number of subjects: 6
Study 36256673 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation with FET
Number of subjects: 6
Study 33827349 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Cycling Exercise on Land (HIIE-L)
Number of subjects: 10
Study 33827349 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Cycling Exercise in Water (HIIE-A)
Number of subjects: 10
Study 33827349 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CONT)
Number of subjects: 10
Study 34101918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 42
Study 34101918 — intervention group
Group type: COMPARATOR
Intervention: Sublingual dexmedetomidine
Number of subjects: 42
Study 33479044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 1324
Study 33479044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 1324
Study 33479044 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural physical activity interventions
Number of subjects: 1324
Study 33479044 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity experience
Number of subjects: 1324
Study 33479044 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD exacerbations
Number of subjects: 1324
Study 33479044 — intervention group
Group type: EXPERIMENTAL
Intervention: D-PPAC and C-PPAC instruments
Number of subjects: 1324
Study 33109218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat 1000 mg
Number of subjects: 0
Study 33109218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat 4000 mg
Number of subjects: 0
Study 33109218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucerastat (up to 4000 mg)
Number of subjects: 0
Study 33109218 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 0
Study 35928975 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Lamaze breathing
Number of subjects: 85
Study 35928975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 85
Study 34225174 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 241
Study 34225174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal Supplemental Oxygen (NSO)
Number of subjects: 241
Study 34225174 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyle and Sleep Hygiene Education (HLSE)
Number of subjects: 241
Study 34225174 — intervention group
Group type: EXPERIMENTAL
Intervention: SQI (Sleep Quality Index) improvement
Number of subjects: 241
Study 34225174 — intervention group
Group type: EXPERIMENTAL
Intervention: SAI (Sleep Apnea Indicator) increase
Number of subjects: 241
Study 34225174 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-sleep fragmentation (eLFCBB) increase
Number of subjects: 241
Study 35978342 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (30 mg/kg/day) with isoniazid and pyrazinamide for 12 weeks after culture conversion.
Number of subjects: 926
Study 35978342 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with isoniazid, rifampicin (10 mg/kg/day), ethambutol, and pyrazinamide for 6 months.
Number of subjects: 926
Study 35978342 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin regimen.
Number of subjects: 926
Study 34762532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level green laser (532 nm, 15 J/cm2 per treatment site)
Number of subjects: 48
Study 34762532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) desensitizer
Number of subjects: 48
Study 34762532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water and placebo laser)
Number of subjects: 48
Study 32867996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined plant oils supplementation (POC)
Number of subjects: 720
Study 32867996 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (CON)
Number of subjects: 720
Study 32867996 — intervention group
Group type: COMPARATOR
Intervention: Aureomycin supplementation (AGP)
Number of subjects: 720
Study 36239176 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous implant placement
Number of subjects: 16
Study 36239176 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement (control)
Number of subjects: 16
Study 32915276 — intervention group
Group type: EXPERIMENTAL
Intervention: AT LARA 829MP (EDOF)
Number of subjects: 211
Study 32915276 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Symfony (EDOF)
Number of subjects: 211
Study 32915276 — intervention group
Group type: COMPARATOR
Intervention: CT ASPHINA 409MP (monofocal)
Number of subjects: 211
Study 32915276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EDOF IOLs
Number of subjects: 211
Study 32915276 — intervention group
Group type: EXPERIMENTAL
Intervention: All IOLs
Number of subjects: 211
Study 32958076 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (8 weeks)
Number of subjects: 60
Study 35477518 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.45 mg
Number of subjects: 306
Study 35477518 — intervention group
Group type: COMPARATOR
Intervention: Iberdomide (0.15 mg, 0.3 mg, 0.45 mg)
Number of subjects: 306
Study 34922521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-shaped incision technique in thick-gingiva group
Number of subjects: 55
Study 34922521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-shaped incision technique in thin-gingiva group
Number of subjects: 55
Study 34922521 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 55
Study 34618017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts (MAG)
Number of subjects: 1466
Study 34618017 — intervention group
Group type: COMPARATOR
Intervention: Single arterial grafts (SAG)
Number of subjects: 1466
Study 34618017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts (MAG) in patients with three-vessel disease
Number of subjects: 1466
Study 34618017 — intervention group
Group type: COMPARATOR
Intervention: Single arterial grafts (SAG) in patients with three-vessel disease
Number of subjects: 1466
Study 34618017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts (MAG) in patients with left main disease
Number of subjects: 1466
Study 34618017 — intervention group
Group type: COMPARATOR
Intervention: Single arterial grafts (SAG) in patients with left main disease
Number of subjects: 1466
Study 33323914 — intervention group
Group type: COMPARATOR
Intervention: Discordant treatment (DisTG)
Number of subjects: 80
Study 33323914 — intervention group
Group type: COMPARATOR
Intervention: Concordant treatment (ConTG)
Number of subjects: 80
Study 33323914 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (both DisTG and ConTG)
Number of subjects: 80
Study 33295070 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified wet suction technique (MWEST)
Number of subjects: 50
Study 33295070 — intervention group
Group type: COMPARATOR
Intervention: Dry suction technique (DST)
Number of subjects: 50
Study 32275777 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor
Number of subjects: 140
Study 32275777 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study 35820990 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal school-based mindfulness training (SBMT)
Number of subjects: 679
Study 35820990 — intervention group
Group type: COMPARATOR
Intervention: Teaching as usual (TAU)
Number of subjects: 679
Study 34700768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) with individualized array placement, delivering doses over 2.5 mW/cm3
Number of subjects: 1
Study 34700768 — intervention group
Group type: EXPERIMENTAL
Intervention: Transducer array layouts targeting the tumor
Number of subjects: 1